Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Payables (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Payables for 4 consecutive years, with $6.3 million as the latest value for Q4 2025.

  • Quarterly Payables rose 74.69% to $6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, up 74.69% year-over-year, with the annual reading at $6.3 million for FY2025, 74.69% up from the prior year.
  • Payables hit $6.3 million in Q4 2025 for Taysha Gene Therapies, up from $5.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $24.0 million in Q2 2022 to a low of $3.6 million in Q4 2024.
  • Historically, Payables has averaged $9.8 million across 4 years, with a median of $8.2 million in 2024.
  • Biggest five-year swings in Payables: plummeted 59.08% in 2023 and later skyrocketed 74.69% in 2025.
  • Year by year, Payables stood at $10.9 million in 2022, then crashed by 41.84% to $6.4 million in 2023, then tumbled by 43.58% to $3.6 million in 2024, then surged by 74.69% to $6.3 million in 2025.
  • Business Quant data shows Payables for TSHA at $6.3 million in Q4 2025, $5.4 million in Q3 2025, and $7.7 million in Q2 2025.